Probiotix Health PLC
F:X90
Probiotix Health PLC
ProBiotix Health Plc develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The company is headquartered in York, North Yorkshire and currently employs 2 full-time employees. The company went IPO on 2022-03-31. The firm develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company manufactures cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (LP-LDL). ProBiotix commercializes LP-LDL as an ingredient and in a range of white and own-label products under its CholBiome range. The CholBiome portfolio consists of four products, namely CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH. LP-LDL helps to improve blood lipid profiles and blood pressure. The firm's development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. These platforms are applicable across a range of other human diseases. The firm is focused on identifying and developing microbial strains, compounds, and formulations for use in the nutraceutical industry.
ProBiotix Health Plc develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The company is headquartered in York, North Yorkshire and currently employs 2 full-time employees. The company went IPO on 2022-03-31. The firm develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company manufactures cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (LP-LDL). ProBiotix commercializes LP-LDL as an ingredient and in a range of white and own-label products under its CholBiome range. The CholBiome portfolio consists of four products, namely CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH. LP-LDL helps to improve blood lipid profiles and blood pressure. The firm's development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. These platforms are applicable across a range of other human diseases. The firm is focused on identifying and developing microbial strains, compounds, and formulations for use in the nutraceutical industry.
